The KRAS inhibitors ASP2453, Sotorasib and Adagrasib are the most recently developed KRAS inhibitors with comprehensive published results in vitro and in vivo on their ability to selective inhibit KRAS G12C mutated cancers and downstream pathways. The gene discussed is KRAS; the disease is cancer.